A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 342 participants.

Also called NCT06863987

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 342 participants (planned count) (from the registry)
Sponsor
Shandong New Time Pharmaceutical Co., LTD (from the registry)
Registry
  • NCT NCT06863987
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06863987. Allocation not applicable; double masking; primary purpose treatment. Start 2025-02-05 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
Condition
Essential Hypertension
Intervention (Drug)
Valsartan Oral Solution
Intervention (Drug)
Placebo
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD (class: industry)

Record details

Record id
cardio:ct-nct06863987
Content hash
deb0bd9c643188d6316d9513e55591c9c7f7a866a0a4035c2e6a25d46e5b5084